Biopharmaceutical company Alkermes plc (Nasdaq:ALKS) revealed on Monday the planned resignation of Jim Robinson with effect from 19 April 2019 for personal reasons.
Currently, Robinson serves as the president and chief operating officer in the company.
Alkermes develops medicines for the treatment of central nervous system (CNS) diseases.It has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and oncology.
Headquartered in Dublin, Ireland, the company has an R&D centre in Waltham, Massachusetts, a research and manufacturing facility in Athlone, Ireland and a manufacturing facility in Wilmington, Ohio.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference